UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers

Cancer cell, 2018-10, Vol.34 (4), p.549-560.e9

2018

Volltextzugriff (PDF)

Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment

Nature communications, 2019-02, Vol.10 (1), p.733-17, Article 733

2019

Volltextzugriff (PDF)

Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry

PLoS genetics, 2020-02, Vol.16 (2), p.e1008641

2020

Volltextzugriff (PDF)

DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy

Molecular cancer, 2024-05, Vol.23 (1), p.97-5, Article 97

2024

Volltextzugriff (PDF)

Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia

Nature communications, 2024-06, Vol.15 (1), p.5180-20

2024

Volltextzugriff (PDF)

γδ T cells for immunotherapy

Blood, 2018-11, Vol.132 (21), p.2212-2213

Long, Meixiao

2018

Volltextzugriff (PDF)

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia

Haematologica (Roma), 2021-06, Vol.106 (6), p.1608-1615

2021

Volltextzugriff (PDF)

Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment

Cell reports (Cambridge), 2020-07, Vol.32 (2), p.107884-107884, Article 107884

2020

Volltextzugriff (PDF)

The kinase PDK1 is essential for B-cell receptor mediated survival signaling

PloS one, 2013-02, Vol.8 (2), p.e55378-e55378

2013

Volltextzugriff (PDF)

Nuclear Factor-κB Modulates Regulatory T Cell Development by Directly Regulating Expression of Foxp3 Transcription Factor

Immunity (Cambridge, Mass.), 2009-12, Vol.31 (6), p.921-931

2009

Volltextzugriff (PDF)

Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement

Immunological investigations, 2022-11, Vol.51 (8), p.2176-2214

2022

Volltextzugriff (PDF)

Ibrutinib treatment improves T cell number and function in CLL patients

The Journal of clinical investigation, 2017-08, Vol.127 (8), p.3052-3064

2017

Volltextzugriff (PDF)

CD33‐Targeted Therapies: Beating the Disease or Beaten to Death?

Journal of clinical pharmacology, 2021-01, Vol.61 (1), p.7-17

2021

Volltextzugriff (PDF)

A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment

Blood advances, 2024-01, Vol.8 (2), p.470-481

2024

Volltextzugriff (PDF)

IκBβ acts to inhibit and activate gene expression during the inflammatory response

Nature (London), 2010-08, Vol.466 (7310), p.1115-1119

2010

Volltextzugriff (PDF)

T Regulatory Cells Maintain Intestinal Homeostasis by Suppressing γδ T Cells

Immunity (Cambridge, Mass.), 2010-11, Vol.33 (5), p.791-803

2010

Volltextzugriff (PDF)

T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment

Blood, 2023-11, Vol.142 (Supplement 1), p.4631-4631

2023

Volltextzugriff (PDF)

BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia

Blood advances, 2017-11, Vol.1 (24), p.2147-2160

2017

Volltextzugriff (PDF)

The IKK-neutralizing compound Bay11 kills supereffector CD8 T cells by altering caspase-dependent activation-induced cell death

Journal of leukocyte biology, 2009-01, Vol.85 (1), p.175-185

2009

Volltextzugriff (PDF)

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood, 2021-11, Vol.138 (Supplement 1), p.3846-3846

2021

Volltextzugriff (PDF)

Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.5683-5683

2018

Volltextzugriff (PDF)

Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT244-CT244

2021

Volltextzugriff (PDF)

SUSD2 suppresses CD8 + T cell antitumor immunity by targeting IL-2 receptor signaling

Nature immunology, 2022-11, Vol.23 (11), p.1588-1599

2022

Volltextzugriff (PDF)

PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

The Journal of clinical investigation, 2019-01, Vol.129 (1), p.122-136

2019

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(82)

Publikationsform

Artikel
(91)
Dissertationen
(1)

Sprache

Englisch
(92)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(31)
Animals
(21)
Humans
(20)
Mice
(19)
Immunology
(12)
Hematology
(10)
Mice, Transgenic
(10)
Male
(9)
Oncology
(9)
Female
(8)
Cancer
(7)
Cd4-Positive T-Lymphocytes - Immunology
(7)
Cell Biology
(7)
Adoptive Transfer
(6)
Immunotherapy
(6)
Kinases
(6)
Signal Transduction
(6)
Chronic Lymphocytic Leukemia
(5)
Leukemia
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(17)
The Journal Of Immunology
(12)
Immunity
(10)
Blood Advances
(5)
Cancer Research
(5)
Journal Of Clinical Oncology
(5)
Nature
(5)
The Journal Of Clinical Investigation
(4)
The journal Of Immunology/the journal Of Immunology
(4)
Cell Reports
(3)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers

Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment

Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry

DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy

Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia

γδ T cells for immunotherapy

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia

Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment

The kinase PDK1 is essential for B-cell receptor mediated survival signaling

Nuclear Factor-κB Modulates Regulatory T Cell Development by Directly Regulating Expression of Foxp3 Transcription Factor

Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement

Ibrutinib treatment improves T cell number and function in CLL patients

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

CD33‐Targeted Therapies: Beating the Disease or Beaten to Death?

A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment

IκBβ acts to inhibit and activate gene expression during the inflammatory response

T Regulatory Cells Maintain Intestinal Homeostasis by Suppressing γδ T Cells

T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment

BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia

The IKK-neutralizing compound Bay11 kills supereffector CD8 T cells by altering caspase-dependent activation-induced cell death

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia

Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

SUSD2 suppresses CD8 + T cell antitumor immunity by targeting IL-2 receptor signaling

PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

Suchergebnisse filtern